Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06812390

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

Led by Anahita Rabiee MD MHS · Updated on 2025-03-11

20

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

A

Anahita Rabiee MD MHS

Lead Sponsor

G

Grifols Shared Services North America, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.

CONDITIONS

Official Title

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Outpatient patients with decompensated cirrhosis with past or current ascites and persistent lower extremity edema despite oral diuretic titration
  • Serum albumin less than 3.5 g/dL
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • Patients with estimated glomerular filtration rate less than 30 mL/min/1.73 m2
  • Changes in oral diuretic regimen in the past 7 days (patients can enter after 7 days)
  • Large volume paracentesis in the past 7 days (patients can enter after 7 days)
  • Albumin infusion within the previous 14 days (patients can enter after 14 days)
  • Spontaneous bacterial peritonitis in the past month
  • Active variceal bleeding
  • Current hepatic encephalopathy grade 2 or higher
  • Use of other diuretics such as hydrochlorothiazide (amiloride or eplerenone acceptable replacements for spironolactone, Bumex or Torsemide acceptable replacements for furosemide)
  • Hypotension (mean arterial pressure less than 65 mmHg or systolic blood pressure less than 90 mmHg)
  • Severe low sodium (less than 125 mEq/L)
  • Previous diagnosis of overt heart failure with systolic ejection fraction less than 50%
  • Baseline oxygen requirement
  • Allergy to albumin preparations

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

West Haven VA Medical Center

West Haven, Connecticut, United States, 06516

Actively Recruiting

Loading map...

Research Team

A

Anahita Rabiee, MD, MHS

CONTACT

L

Lynn F. Buchwalder, M.S.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here